Get the Stockscreener App
16.57
1.35%
0.22
Pre-market:
16.64
0.07
+0.42%
Personalis Inc stock is traded at $16.57, with a volume of 1.71M.
It is up +1.35% in the last 24 hours and down -2.87% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$16.35
Open:
$16.16
24h Volume:
1.71M
Relative Volume:
0.44
Market Cap:
$1.77B
Revenue:
$64.52M
Net Income/Loss:
$-95.55M
P/E Ratio:
-16.29
EPS:
-1.0169
Net Cash Flow:
$-84.65M
1W Performance:
+2.09%
1M Performance:
-2.87%
6M Performance:
+112.98%
1Y Performance:
+173.43%
1-Day Range:
$16.10
$16.63
1-Week Range:
$16.07
$16.63
52-Week Range:
$4.955
$18.89
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
16.57 | 1.77B | 64.52M | -95.55M | -84.65M | -1.0169 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - Supply Chain Digital Magazine
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewswire Inc.
Tempus AI shares rise 5.1% to $70 on Moderna cancer trial validation - scanx.trade
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight - Stocktwits
Personalis, Inc. (PSNL) Stock Analysis: A Bold Bet in Cancer Genomics with a 30% Revenue Surge - DirectorsTalk Interviews
Tempus move on Personalis (NASDAQ: PSNL) hinges on cancer tests and data from 50 million patients - Stock Titan
Tempus AI (TEM) Rallies As Upgrade, Earnings And Personalis Deal Align - timothysykes.com
Why Is PSNL Stock Up 5% After-Hours? - Stocktwits
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Weekly Recap: Intismeran win and Personalis 13% stake backs Tempus AI - TradingView
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation - finance.biggo.com
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. - WSJ
Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next. - webull.com
Personalis Inc Stock Historical Valuations | FRA:04X - GuruFocus
Personalis Inc Stock Operating Data - GuruFocus
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? - finance.yahoo.com
Why Personalis (PSNL) Is Up 24.0% After New VA MVP Genomics Task Order Win - webull.com
Personalis falls amid a downgrade as a competitive bid appears unlikely - Seeking Alpha
Tempus AI soars 40% in a week, adding $3.7 billion—over double the Personalis acquisition amount - TechStock²
Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis DealWhat's Changed - finance.yahoo.com
A Look at Personalis Inc (PSNL) After 8.8% Gain -- GF Value $2.4 - GuruFocus
Tempus AI Shares Jump $3 Billion After Moderna Victory Boosts Value of $1.5 Billion Personalis Stake - TechStock²
Has Tempus AI (TEM) Run Too Far Ahead Of Its Valuation Narrative? - finance.yahoo.com
AMERIPRISE FINANCIAL INC Trims Personalis Inc (PSNL) Stake -- Shares Trade 590% Above GF Value - GuruFocus
Why Tempus AI (TEM) Is Up 22.8% After Buying the Platform Behind a Key mRNA Cancer Win - simplywall.st
Deep Track Capital, LP Trims Personalis Inc (PSNL) Stake -- Shar - GuruFocus
Personalis secures new Million Veteran Program task order - TipRanks
Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP - TradingView
Personalis wins up to $18.3M VA MVP task order, cumulative VA awards reach $243.3M - TradingView
Personalis (NASDAQ: PSNL) wins Million Veteran Program task order—how big is it? - Stock Titan
Tempus soars on coattails of Moderna/Merck cancer vaccine - Crain's Chicago Business
Personalis stock reaches 52-week high at 16.42 USD - Investing.com
Personalis stock reaches 52-week high at 16.42 USD By Investing.com - Investing.com Canada
Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM) - Seeking Alpha
Personalis | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Personalis Inc : PSNL - 247wallst.com
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant - Yahoo Finance
Tempus AI Jumps 24% as Merck-Moderna mRNA Vaccine Win Lifts Personalis Deal - finance.biggo.com
TEM Stock Dips As Tempus AI Bets $1.5B On Personalis - StocksToTrade
Personalis Inc. (PSNL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
Tempus AI Stock Slides As $1.5B Personalis Bet Raises Stakes - timothysykes.com
What Personalis (PSNL)'s Rising Revenue But Deepening Losses Means For Shareholders - webull.com
Tempus Is Buying Cancer-Testing Partner Personalis for $1.5 Billion - RamaOnHealthcare
Ameriprise Financial (PSNL) discloses 5.8% ownership stake in Personalis common stock - Stock Titan
Deep Track Capital (PSNL) reports 4,000,000 Personalis shares, now under 5% ownership - Stock Titan
Sei Investments Co. Buys 83,040 Shares of Personalis, Inc. $PSNL - MarketBeat
Personalis, Inc. (PSNL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Personalis Inc (PSNL) Shares Fall 3.2% -- What GF Score of 53 Te - GuruFocus
Personalis, Inc. $PSNL Stock Holdings Lifted by Dimensional Fund Advisors LP - MarketBeat
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):